154057-58-6

Basic information

• Product Name: [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido
• Synonyms: [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido;[[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]triphenylphosphonium bromide;2-Cyclopropyl-4-(4-fluoropenyl)-quinolyl-3-Methyltriphenyl BroMide;Pitavastatin InterMediate;2-Cyclopropyl-4-(4-flourophenyl)-quinolyl-3-Methyl triphenylbroMide;((2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methyl)triphenylphosphonium bromide;PB3-2;((2-Cyclopropyl-4-(4-fluorophenyl)
• CAS NO: 154057-58-6
• Molecular Formula: C37H30BrFNP
• Molecular Weight: 618.5169642
• EINECS: 1312995-182-4
• Mol File: 154057-58-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 218-225℃
• Appearance: White crystalline powder
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• CAS DataBase Reference: [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido(CAS DataBase Reference)
• NIST Chemistry Reference: [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido(154057-58-6)
• EPA Substance Registry System: [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido(154057-58-6)

Safety Data

• Hazardous Substances Data: 154057-58-6(Hazardous Substances Data)

Usage

Uses

[[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]triphenyl-phosphonium Bromide is an impurity from the synthesis of HMG-CoA reductase inhibitor Pitavastatin [P531040, (Z)-Pitavastatin Calcium Salt].

Upstream product

• 6399-81-1 triphenylphosphine hydrobromide 
• 121660-11-5 2-cyclopropyl-4-(4-fluorophenyl)-3-(hydroxymethyl)quinoline 
• 121659-86-7 methyl 4-(4'-fluorophenyl)-2-cyclopropylquinoline-3-carboxylate 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 765-43-5 Cyclopropyl methyl ketone 
• 603-35-0 triphenylphosphine 
• 154057-56-4 3-(bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)-quinoline 
• 121660-37-5 2-cyclopropyl-4-(4-fluorophenyl)-3-formylquinoline 

Downstream Products

• 147511-70-4 (R)-1-phenylethanamine (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate 
• 147489-06-3 (4R,6S)-(E)-{6-[2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid tert-butyl ester 

Relevant articles and documents

A novel preparation method of a pitavastatin calcium intermediate

The invention relates to a preparation method of [[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]triphenylphosphonium bromide, comprising the following steps: reacting 2-Cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-methanol and triphenylphosphine hydrobromide in an organic solvent to obtain a target compound. The preparation method provided by the invention has the advantages of easily available raw materials, simple operation and high yield, effectively reduces phosphorus-containing wastewater and phosphorus-containing waste residues, reduces the production cost, and is beneficial to large-scale production.

The use of a lactonized statin side-chain precursor in a concise and efficient assembly of pitavastatin

A concise and simple synthetic route to pitavastatin is described. The approach involves a highly stereoselective Wittig olefination reaction between a lactonized statin side-chain precursor and the triphenylphosphonium bromide salt of the corresponding quinoline heterocyclic core. The necessary O-tert-butyl(dimethyl)silyl-protected pitavastatin lactone was obtained in 75% yield and high purity by simple crystallization from aqueous methanol. Subsequent deprotection, hydrolysis, and cation exchange in a one-pot operation provided pitavastatin calcium in 93% yield. Georg Thieme Verlag Stuttgart · New York.

PITAVASTATIN CALCIUM AND PROCESS FOR ITS PREPARATION

The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.